A Decade of Cardiovascular Fear Around Testosterone, Finally Addressed

The relationship between testosterone therapy and heart disease has been one of the most contentious topics in men's health for over a decade. In 2013 and 2014, two widely publicized observational studies suggested that testosterone replacement therapy increased cardiovascular risk. Despite significant methodological criticisms of both studies, the FDA responded in 2015 by adding a cardiovascular warning to all testosterone product labels, and many clinicians became reluctant to prescribe.

The subsequent correspondence in the New England Journal of Medicine following the TRAVERSE trial results helped clarify the scientific record. The primary finding held: testosterone replacement therapy was noninferior to placebo for major adverse cardiovascular events, including heart attack, stroke, and cardiovascular death. For men who had spent years avoiding treatment out of cardiovascular fear, this was significant reassurance grounded in a randomized controlled trial rather than observational data.

But the NEJM discussion also emphasized signals that should not be ignored. The testosterone group experienced higher rates of nonfatal arrhythmias, particularly atrial fibrillation, and modestly elevated venous thromboembolic events. These are not reasons to avoid TRT entirely, but they are reasons to monitor patients carefully rather than treating testosterone therapy as a set-it-and-forget-it prescription.

The Androgen Society later published a position paper in Mayo Clinic Proceedings reinforcing that when testosterone therapy is used as indicated in genuinely hypogonadal men, the cardiovascular risk profile is acceptable. The problem arises when therapy is initiated without proper diagnosis, without baseline cardiovascular assessment, and without ongoing monitoring.

The Tracking Connection

Kairos™ exists because monitoring makes therapy safer. By tracking cardiovascular biomarkers, resting heart rate trends, blood pressure, hematocrit, and lipid panels alongside testosterone levels over time, Kairos gives both patients and providers an early warning system. If arrhythmia risk factors begin to emerge, the data is already there, not buried in an unconnected chart at a separate cardiology office.